PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (Paris:STNT)(FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® coronary stent, today announced that the Company’s Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS’ product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
Help employers find you! Check out all the jobs and post your resume.
